Kihara James 4

What Happened
James Kihara, Principal Accounting Officer at ACADIA Pharmaceuticals (ACAD), reported the sale of 11,421 shares in an open-market/private sale on June 26, 2026. The reported weighted-average price was $26.08 per share, for total proceeds of approximately $297,912. This was a sale (S), not a purchase.

Key Details

• Transaction date: 2026-06-26 (reported on Form 4 filed 2026-06-29). Filing was within the required two-business-day window.
• Price: weighted average $26.08; shares were sold in multiple trades at prices ranging from $25.88 to $26.265 (per footnote).
• Shares sold: 11,421; total reported proceeds ≈ $297,912.
• Shares owned after transaction: not provided in the material you supplied.
• Footnotes: Transaction occurred under a Rule 10b5-1 trading plan adopted by Kihara on December 9, 2025 (F1). F2 notes the weighted-average price and that detailed per-trade prices are available on request.

Context
This sale was executed under a pre-established 10b5-1 plan, which typically means the trades were pre-planned and may be routine rather than a real-time signal about company prospects. Sales are common for insiders to diversify or meet cash needs; purchases are generally considered more informative about insider sentiment. The filing appears timely.